Novartis
NEWS
The FDA is slowing down the process of potentially approving dozens of new medications initially developed for the Chinese market.
The COVID-19 pandemic has seen a full-blown effort from biopharma and researchers to develop new drugs and test old ones against the disease, with highly mixed results.
Novartis CEO Vas Narasimhan and Roche CEO Severin Schwan saw revenue growth for the past year, and each took home more than $12 million in total compensation for 2021.
Novartis reported its full-year financials this week for 2021, and overall, the news was good. Of concern, however, is the company’s Sandoz generics unit.
J&J said it was terminating development of bermekimab for atopic dermatitis after looking at additional efficacy data.
Even as Novartis entertains the potential sale of Sandoz, the company is lauding growth in its biosimilars business that is expected to stabilize its future development.
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.
For a look at what’s going on with kids and COVID-19, and related stories, continue reading.
JOBS
IN THE PRESS
